Loading…

Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication

To compare the effects of two premedication regimens on cardiorespiratory variables, sedation, and anxiety in patients scheduled for coronary artery bypass graft (CABG) surgery. This was a prospective randomized, double-blind clinical trial. Sixty-eight patients were monitored for 1.5 hr before and...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of anesthesia 1997-02, Vol.44 (2), p.146-153
Main Authors: SACCOMANNO, P. M, KAVANAGH, B. P, CHENG, D. C, KATZ, J, SANDLER, A. N
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63
cites cdi_FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63
container_end_page 153
container_issue 2
container_start_page 146
container_title Canadian journal of anesthesia
container_volume 44
creator SACCOMANNO, P. M
KAVANAGH, B. P
CHENG, D. C
KATZ, J
SANDLER, A. N
description To compare the effects of two premedication regimens on cardiorespiratory variables, sedation, and anxiety in patients scheduled for coronary artery bypass graft (CABG) surgery. This was a prospective randomized, double-blind clinical trial. Sixty-eight patients were monitored for 1.5 hr before and 2.0 hr after premedication with lorazepam (0.03 mg.kg-1 sl), morphine (0.15 mg.kg-1 im), and perphenazine (0.05 mg.kg-1 im) [Group 1], or with lorazepam (0.03 mg.kg-1 sl) and saline (1.5 ml im) [Group 2]. All were continuously monitored with a 12-lead ECG ST monitors, respiratory inductive plethysmography (RIP), digital pulse oximetry, intra-arterial blood pressure, and arterial blood gas analysis. Sedation and anxiety scores were also recorded. The incidence and duration of myocardial ischaemia was low and similar in Groups 1 and 2. Patients in Group 1, but not in Group 2, had a greater number of events (P < 0.04) and duration (P < 0.02) of O2 desaturation; higher PaCO2 (P < 0.001), and more haemodynamic events (P < 0.006) after premedication when compared with baseline. There was no difference in RIP or ECG variables between the two groups. Following premedication, both groups reported reduced anxiety scores and elevated sedation scores (P < 0.01), with sedation greater in Group 1 than in Group 2 (P < 0.01). In CABG patients, premedication with lorazepam provides adequate anxiolysis and sedation, and the addition of morphine and perphenazine results in elevated PaCO2, arterial haemoglobin desaturation, and potentially adverse haemodynamic changes.
doi_str_mv 10.1007/BF03013002
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78848130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2591062591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63</originalsourceid><addsrcrecordid>eNpdkM1L5EAQxRtRxtH14l1oRDyI2a2kP3PUwdldELwoeIuV7g5Gku7YPSOsf729zKDgqaj3fjyqHiHHJfwsAdSv6yUwKBlAtUPmJa9loWsldskcNKsKWcLjPjlI6QUAtBR6RmY1cKYqOSdPizBOGPsUPA0dHULEdzfhSHEI3tG39CVd0jHE6bn37pKit3RyeXMe37NCuxCpwWh7NHSKbnS2N7jqg_9B9jockjvazkPysLy5X_wpbu9-_11c3RaGKb4qKpRKIrbWWAlWW6NaIWvLdc2NEmikcLVRTIpW1IhCSy64xla6TpYVWMkOyfkmd4rhde3Sqhn7ZNwwoHdhnRqlNde5owyefgNfwjr6fFtTVxUHYJpn6GIDmRhSiq5rptiPGP81JTT_O2--Os_wyTZx3ebHP9Ftydk_2_qYDA5dRG_69IlVQkkmgH0Ae1-Iig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>922400384</pqid></control><display><type>article</type><title>Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication</title><source>Springer Nature</source><creator>SACCOMANNO, P. M ; KAVANAGH, B. P ; CHENG, D. C ; KATZ, J ; SANDLER, A. N</creator><creatorcontrib>SACCOMANNO, P. M ; KAVANAGH, B. P ; CHENG, D. C ; KATZ, J ; SANDLER, A. N</creatorcontrib><description><![CDATA[To compare the effects of two premedication regimens on cardiorespiratory variables, sedation, and anxiety in patients scheduled for coronary artery bypass graft (CABG) surgery. This was a prospective randomized, double-blind clinical trial. Sixty-eight patients were monitored for 1.5 hr before and 2.0 hr after premedication with lorazepam (0.03 mg.kg-1 sl), morphine (0.15 mg.kg-1 im), and perphenazine (0.05 mg.kg-1 im) [Group 1], or with lorazepam (0.03 mg.kg-1 sl) and saline (1.5 ml im) [Group 2]. All were continuously monitored with a 12-lead ECG ST monitors, respiratory inductive plethysmography (RIP), digital pulse oximetry, intra-arterial blood pressure, and arterial blood gas analysis. Sedation and anxiety scores were also recorded. The incidence and duration of myocardial ischaemia was low and similar in Groups 1 and 2. Patients in Group 1, but not in Group 2, had a greater number of events (P < 0.04) and duration (P < 0.02) of O2 desaturation; higher PaCO2 (P < 0.001), and more haemodynamic events (P < 0.006) after premedication when compared with baseline. There was no difference in RIP or ECG variables between the two groups. Following premedication, both groups reported reduced anxiety scores and elevated sedation scores (P < 0.01), with sedation greater in Group 1 than in Group 2 (P < 0.01). In CABG patients, premedication with lorazepam provides adequate anxiolysis and sedation, and the addition of morphine and perphenazine results in elevated PaCO2, arterial haemoglobin desaturation, and potentially adverse haemodynamic changes.]]></description><identifier>ISSN: 0832-610X</identifier><identifier>EISSN: 1496-8975</identifier><identifier>DOI: 10.1007/BF03013002</identifier><identifier>PMID: 9043726</identifier><identifier>CODEN: CJOAEP</identifier><language>eng</language><publisher>Toronto, ON: Canadian Anesthesiologists' Society</publisher><subject>Aged ; Anesthesia ; Anti-Anxiety Agents - pharmacology ; Anxiety ; Biological and medical sciences ; Double-Blind Method ; Female ; Hemodynamics - drug effects ; Hemoglobins - metabolism ; Humans ; Hypnotics. Sedatives ; Lorazepam - administration &amp; dosage ; Lorazepam - pharmacology ; Male ; Medical sciences ; Middle Aged ; Morphine - administration &amp; dosage ; Myocardial Ischemia - etiology ; Myocardial Ischemia - prevention &amp; control ; Neuropharmacology ; Perphenazine - administration &amp; dosage ; Pharmacology. Drug treatments ; Preanesthetic Medication ; Prospective Studies ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Respiration - drug effects</subject><ispartof>Canadian journal of anesthesia, 1997-02, Vol.44 (2), p.146-153</ispartof><rights>1997 INIST-CNRS</rights><rights>Canadian Anesthesiologists 1997.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63</citedby><cites>FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2576350$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9043726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SACCOMANNO, P. M</creatorcontrib><creatorcontrib>KAVANAGH, B. P</creatorcontrib><creatorcontrib>CHENG, D. C</creatorcontrib><creatorcontrib>KATZ, J</creatorcontrib><creatorcontrib>SANDLER, A. N</creatorcontrib><title>Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication</title><title>Canadian journal of anesthesia</title><addtitle>Can J Anaesth</addtitle><description><![CDATA[To compare the effects of two premedication regimens on cardiorespiratory variables, sedation, and anxiety in patients scheduled for coronary artery bypass graft (CABG) surgery. This was a prospective randomized, double-blind clinical trial. Sixty-eight patients were monitored for 1.5 hr before and 2.0 hr after premedication with lorazepam (0.03 mg.kg-1 sl), morphine (0.15 mg.kg-1 im), and perphenazine (0.05 mg.kg-1 im) [Group 1], or with lorazepam (0.03 mg.kg-1 sl) and saline (1.5 ml im) [Group 2]. All were continuously monitored with a 12-lead ECG ST monitors, respiratory inductive plethysmography (RIP), digital pulse oximetry, intra-arterial blood pressure, and arterial blood gas analysis. Sedation and anxiety scores were also recorded. The incidence and duration of myocardial ischaemia was low and similar in Groups 1 and 2. Patients in Group 1, but not in Group 2, had a greater number of events (P < 0.04) and duration (P < 0.02) of O2 desaturation; higher PaCO2 (P < 0.001), and more haemodynamic events (P < 0.006) after premedication when compared with baseline. There was no difference in RIP or ECG variables between the two groups. Following premedication, both groups reported reduced anxiety scores and elevated sedation scores (P < 0.01), with sedation greater in Group 1 than in Group 2 (P < 0.01). In CABG patients, premedication with lorazepam provides adequate anxiolysis and sedation, and the addition of morphine and perphenazine results in elevated PaCO2, arterial haemoglobin desaturation, and potentially adverse haemodynamic changes.]]></description><subject>Aged</subject><subject>Anesthesia</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anxiety</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Hemodynamics - drug effects</subject><subject>Hemoglobins - metabolism</subject><subject>Humans</subject><subject>Hypnotics. Sedatives</subject><subject>Lorazepam - administration &amp; dosage</subject><subject>Lorazepam - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morphine - administration &amp; dosage</subject><subject>Myocardial Ischemia - etiology</subject><subject>Myocardial Ischemia - prevention &amp; control</subject><subject>Neuropharmacology</subject><subject>Perphenazine - administration &amp; dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Preanesthetic Medication</subject><subject>Prospective Studies</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Respiration - drug effects</subject><issn>0832-610X</issn><issn>1496-8975</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNpdkM1L5EAQxRtRxtH14l1oRDyI2a2kP3PUwdldELwoeIuV7g5Gku7YPSOsf729zKDgqaj3fjyqHiHHJfwsAdSv6yUwKBlAtUPmJa9loWsldskcNKsKWcLjPjlI6QUAtBR6RmY1cKYqOSdPizBOGPsUPA0dHULEdzfhSHEI3tG39CVd0jHE6bn37pKit3RyeXMe37NCuxCpwWh7NHSKbnS2N7jqg_9B9jockjvazkPysLy5X_wpbu9-_11c3RaGKb4qKpRKIrbWWAlWW6NaIWvLdc2NEmikcLVRTIpW1IhCSy64xla6TpYVWMkOyfkmd4rhde3Sqhn7ZNwwoHdhnRqlNde5owyefgNfwjr6fFtTVxUHYJpn6GIDmRhSiq5rptiPGP81JTT_O2--Os_wyTZx3ebHP9Ftydk_2_qYDA5dRG_69IlVQkkmgH0Ae1-Iig</recordid><startdate>19970201</startdate><enddate>19970201</enddate><creator>SACCOMANNO, P. M</creator><creator>KAVANAGH, B. P</creator><creator>CHENG, D. C</creator><creator>KATZ, J</creator><creator>SANDLER, A. N</creator><general>Canadian Anesthesiologists' Society</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19970201</creationdate><title>Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication</title><author>SACCOMANNO, P. M ; KAVANAGH, B. P ; CHENG, D. C ; KATZ, J ; SANDLER, A. N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Anesthesia</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anxiety</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Hemodynamics - drug effects</topic><topic>Hemoglobins - metabolism</topic><topic>Humans</topic><topic>Hypnotics. Sedatives</topic><topic>Lorazepam - administration &amp; dosage</topic><topic>Lorazepam - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morphine - administration &amp; dosage</topic><topic>Myocardial Ischemia - etiology</topic><topic>Myocardial Ischemia - prevention &amp; control</topic><topic>Neuropharmacology</topic><topic>Perphenazine - administration &amp; dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Preanesthetic Medication</topic><topic>Prospective Studies</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Respiration - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SACCOMANNO, P. M</creatorcontrib><creatorcontrib>KAVANAGH, B. P</creatorcontrib><creatorcontrib>CHENG, D. C</creatorcontrib><creatorcontrib>KATZ, J</creatorcontrib><creatorcontrib>SANDLER, A. N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business &amp; Current Affairs Database</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SACCOMANNO, P. M</au><au>KAVANAGH, B. P</au><au>CHENG, D. C</au><au>KATZ, J</au><au>SANDLER, A. N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication</atitle><jtitle>Canadian journal of anesthesia</jtitle><addtitle>Can J Anaesth</addtitle><date>1997-02-01</date><risdate>1997</risdate><volume>44</volume><issue>2</issue><spage>146</spage><epage>153</epage><pages>146-153</pages><issn>0832-610X</issn><eissn>1496-8975</eissn><coden>CJOAEP</coden><abstract><![CDATA[To compare the effects of two premedication regimens on cardiorespiratory variables, sedation, and anxiety in patients scheduled for coronary artery bypass graft (CABG) surgery. This was a prospective randomized, double-blind clinical trial. Sixty-eight patients were monitored for 1.5 hr before and 2.0 hr after premedication with lorazepam (0.03 mg.kg-1 sl), morphine (0.15 mg.kg-1 im), and perphenazine (0.05 mg.kg-1 im) [Group 1], or with lorazepam (0.03 mg.kg-1 sl) and saline (1.5 ml im) [Group 2]. All were continuously monitored with a 12-lead ECG ST monitors, respiratory inductive plethysmography (RIP), digital pulse oximetry, intra-arterial blood pressure, and arterial blood gas analysis. Sedation and anxiety scores were also recorded. The incidence and duration of myocardial ischaemia was low and similar in Groups 1 and 2. Patients in Group 1, but not in Group 2, had a greater number of events (P < 0.04) and duration (P < 0.02) of O2 desaturation; higher PaCO2 (P < 0.001), and more haemodynamic events (P < 0.006) after premedication when compared with baseline. There was no difference in RIP or ECG variables between the two groups. Following premedication, both groups reported reduced anxiety scores and elevated sedation scores (P < 0.01), with sedation greater in Group 1 than in Group 2 (P < 0.01). In CABG patients, premedication with lorazepam provides adequate anxiolysis and sedation, and the addition of morphine and perphenazine results in elevated PaCO2, arterial haemoglobin desaturation, and potentially adverse haemodynamic changes.]]></abstract><cop>Toronto, ON</cop><pub>Canadian Anesthesiologists' Society</pub><pmid>9043726</pmid><doi>10.1007/BF03013002</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0832-610X
ispartof Canadian journal of anesthesia, 1997-02, Vol.44 (2), p.146-153
issn 0832-610X
1496-8975
language eng
recordid cdi_proquest_miscellaneous_78848130
source Springer Nature
subjects Aged
Anesthesia
Anti-Anxiety Agents - pharmacology
Anxiety
Biological and medical sciences
Double-Blind Method
Female
Hemodynamics - drug effects
Hemoglobins - metabolism
Humans
Hypnotics. Sedatives
Lorazepam - administration & dosage
Lorazepam - pharmacology
Male
Medical sciences
Middle Aged
Morphine - administration & dosage
Myocardial Ischemia - etiology
Myocardial Ischemia - prevention & control
Neuropharmacology
Perphenazine - administration & dosage
Pharmacology. Drug treatments
Preanesthetic Medication
Prospective Studies
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Respiration - drug effects
title Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T09%3A25%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20lorazepam%20alone%20vs%20lorazepam,%20morphine,%20and%20perphenazine%20for%20cardiac%20premedication&rft.jtitle=Canadian%20journal%20of%20anesthesia&rft.au=SACCOMANNO,%20P.%20M&rft.date=1997-02-01&rft.volume=44&rft.issue=2&rft.spage=146&rft.epage=153&rft.pages=146-153&rft.issn=0832-610X&rft.eissn=1496-8975&rft.coden=CJOAEP&rft_id=info:doi/10.1007/BF03013002&rft_dat=%3Cproquest_cross%3E2591062591%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-2a676aabdcd60d8dc7b569d4894c75ac65e9c7365b59aa5864548ab6ef6120d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=922400384&rft_id=info:pmid/9043726&rfr_iscdi=true